Inovio Pharmaceuticals faces tumultuous stock reaction to $30m offering
Inovio Pharmaceuticals, a biotechnology company specialising in DNA medicines, witnessed a sharp decline in its stock value following the announcement of a $30 million public ... Read More
Precigen gets FDA orphan drug status for PRGN-2012 in RRP
Precigen has secured orphan drug designation (ODD) for PRGN-2012 from the US Food and Drug Administration (FDA) in recurrent respiratory papillomatosis (RRP). PRGN-2012 is an ... Read More